Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddelte i dag, at den europæiske registreringsansøgning for virksomhedens tabletvaccine mod træpollenallergi er accepteret til behandling af de relevante...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the European regulatory filing for its investigational tree pollen sublingual allergy immunotherapy (SLIT) tablet has been accepted for...
-
Bemærk venligst, at kvartalsrapporten kun foreligger på engelsk. Better than expected performance in Q2 (unaudited)ALK’s financial performance in Q2 was better than expected and full-year outlook...
-
Better than expected performance in Q2 (unaudited)ALK’s financial performance in Q2 was better than expected and full-year outlook has been improved. The execution of ALK’s new growth strategy is on...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) offentliggør delårsrapport for første halvår (Q2) 2018 onsdag den 15. august 2018. ALK afholder samme dag kl. 13.30 (CEST) en telefonkonference for...
-
On Wednesday, 15 August 2018, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) releases its interim report for the six months ended 30 June 2018. ALK will host a meeting for analysts and...
-
De kliniske resultater af et fase III studie med ALKs nye tablet til behandling af træpollenallergi (birk, el og hassel) er blandt de mest signifikante, der nogensinde er vist i studier med...
-
Leading allergy researchers present Phase III data on tree SLIT-tablet at EAACI Annual Congress in MunichBirch pollen-based product shown to be effective against multiple tree allergiesEffect shown to...
-
Bemærk venligst, at kvartalsrapporten kun foreligger på engelsk. Performance for the period (unaudited) Financial results in Q1 were better than expected and as a result, ALK has...
-
Performance for the period (unaudited) Financial results in Q1 were better than expected and as a result, ALK has improved its full-year financial outlook. Q1 saw good progress with ALK’s four...